Galenica acquires the entirety of Om Pharma, a fully integrated specialty biotechnology and pharmaceutical Swiss company with a unique expertise in the field of immunology. Om Pharma distributes in more than 90 countries and its products occupy a leading position in their markets.

The acquisition confirms and supports Galenica's growth strategy: Om Pharma strengthens the Vifor Pharma business sector with a successfully established product portfolio in therapeutic areas which excellently complement Vifor Pharma's existing indication areas. Om Pharma's worldwide sales force reinforces deeply Vifor Pharma's network of partners, some of whom already distribute Venofer and Maltofer. Om Pharma will be managed as a profit centre of Vifor Pharma. The acquisition will be accretive for the Galenica Group results already in 2009.

Om Pharma was founded in 1937 and is a fully integrated specialty biotechnology and pharmaceutical company specialising in the research, manufacturing and sale of high quality biotechnological and synthetic drugs. Om Pharma manufactures its products in Switzerland (biotechnological drugs) and Portugal (synthetic drugs). Its products are sold in more than 90 countries mainly via a network of agents and partners, but also via its affiliates in Switzerland, Portugal and Peru.